Apogee Therapeutics Announces Late-Breaker Presentation of 16-Week Data from Phase 2 APEX Trial of APG777 for Moderate-to-Severe Atopic Dermatitis at the Upcoming European Academy of Dermatology and Venereology (EADV) 2025 Congress
APGE(NASDAQ:APGE) SAN FRANCISCO and BOSTON, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (Nasdaq: APGE), a clinical-stage biotechnology company advancing optimized, novel biologics with potential for best-in-class profiles in the largest inflammatory and immunology (I&I) markets, today announced data from the Phase 2 APEX trial of APG777 for moderate-to-severe atopic dermatitis was accepted for a late-breaker oral presentation at the upcoming EADV Congress 2025, to be held in Paris, France from September 17-20, 2025. The Company will also present multiple poster presentations highlighting APG777’s best-in-class potential including data supporting its combination strategy.
Apogee Therapeutics to Participate at the Stifel 2025 Virtual Immunology and Inflammation Forum
APGE(NASDAQ:APGE) SAN FRANCISCO and BOSTON, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (Nasdaq: APGE), today announced that members of management will participate in a fireside chat at the Stifel 2025 Virtual Immunology and Inflammation Forum on Tuesday, September 16, 2025, at 11:30 a.m. E.T.
Why Is Apogee Therapeutics Stock Trading Higher On Monday?
APGEApogee's APG808 cut key asthma biomarker FeNO by 53% at 12 weeks with no severe adverse events, showing potential for long-term maintenance dosing.
Apogee Therapeutics Q1 EPS $(0.95) Beats $(1.25) Estimate
APGEApogee Therapeutics Released Interim Data From Its Phase 1b Trial Of APG808, A Novel Half-life Extended IL-4Rα Antibody, In Patients With Mild-to-moderate Asthma
APGEApogee Therapeutics Cash, Cash Equivalents And Marketable Securities Were $681.4M As Of March 31, 2025 That Supports Runway Into Q1 2028
APGE12 Health Care Stocks Moving In Thursday's After-Market Session
APGECitigroup Initiates Coverage On Apogee Therapeutics with Buy Rating, Announces Price Target of $95
APGEApogee Therapeutics' Investigational Atopic Dermatitis Potential Shows Strong Tolerability, Extended Half-Life in Early Trial
APGEApogee's APG990 Phase 1 data show a 60-day half-life and strong tolerability, supporting long-interval dosing. A 2025 trial will compare APG279 to Dupixent.
Apogee Therapeutics Says Cash, Cash Equivalents And Marketable Securities Of $731.1M As Of December 31, 2024 Is Expected To Provide Cash Runway Into Q1 2028
APGEApogee Therapeutics Announced Interim Phase 1 Results From Its First-in-human Trial Of APG990, The Company Says The Data Exceeded Trial Objectives And Demonstrated An Approximately 60-day Half-life
APGEApogee Therapeutics To Host Conference Call To Report Interim Results From The Phase 1 Healthy Volunteer Trial For APG990 And Provide Combination Strategy Update On March 3, 2025 At 8:30am ET
APGE